William K. Oh, MD, presented “Cardiovascular Side Effects of Advanced Disease Therapies” during the 26th Annual Southwest Prostate Cancer Symposium conference on April 15, 2023, in Scottsdale, Arizona.
How to cite: Oh, William K. “Cardiovascular Side Effects of Advanced Disease Therapies.” April 15, 2023. Accessed Aug 2024. https://grandroundsinurology.com/cardiovascular-side-effects-of-advanced-disease-therapies/
Cardiovascular Side Effects of Advanced Disease Therapies – Summary
William K. Oh, MD, details the common therapies used in advanced prostate cancer, including androgen deprivation therapy (ADT), novel hormonal agents like abiraterone and enzalutamide, and chemotherapies such as docetaxel. He emphasizes that while these treatments are effective in controlling cancer progression and improving survival, they have significant cardiovascular risks.
The lecture presents evidence from multiple studies demonstrating that ADT is associated with an increased risk of cardiovascular events, including myocardial infarction, stroke, and sudden cardiac death. Dr. Oh discusses the underlying mechanisms, such as metabolic changes, increased insulin resistance, and adverse lipid profiles induced by hormone deprivation.
Dr. Oh emphasizes the importance of a multidisciplinary approach in managing patients undergoing these treatments. He advocates for regular cardiovascular monitoring, risk assessment, and the involvement of cardiologists in the care team to mitigate these risks.
About the 26th Annual Southwest Prostate Cancer Symposium:
This conference educated attendees about advances in the management of localized and advanced prostate cancer, with a focus on imaging, technology, and training in the related devices. It included a scientific session, as well as live demonstrations of surgical techniques. You can learn more about the conference here.
ABOUT THE AUTHOR
Dr. William K. Oh is Chief Medical Officer at the Prostate Cancer Foundation (PCF), the world’s leading philanthropic organization dedicated to the eradication of prostate cancer and is also a Clinical Professor of Medicine in the Division of Hematology and Medical Oncology at The Tisch Cancer Institute of the Icahn School of Medicine at Mount Sinai. He is an expert in the management of genitourinary malignancies, including prostate, renal, bladder, and testicular cancers.
Dr. Oh received his MD from New York University School of Medicine. He completed his internship and residency in internal medicine at Brigham and Women’s Hospital in Boston. Dr. Oh completed a fellowship in medical oncology at the Dana-Farber Cancer Institute.
For two years prior to joining PCF, Dr. Oh was the Chief Medical Officer at Sema4, a patient-centered health intelligence company. From 2009-2020, Dr. Oh was Chief of the Division of Hematology and Medical Oncology at the Mount Sinai Health System and Deputy Director of The Tisch Cancer Institute, an NCI-designated cancer center, at Mount Sinai. Dr. Oh spent 14 years at Harvard Medical School and the Dana-Farber Cancer Institute in Boston, including service as Clinical Director of GU Oncology and Associate Professor of Medicine.
Dr. Oh has authored more than 350 original articles, reviews, and book chapters on topics relating to prostate, renal, bladder, and testicular cancers. He has edited three books on prostate cancer. He has served in key invited roles for the American Society of Clinical Oncology (ASCO), the American Cancer Society (ACS), and the American Urological Association (AUA), including the Guidelines Committee for Castration-Resistant Prostate Cancer. In addition to reviewing for prominent journals such as the New England Journal of Medicine, Journal of Clinical Oncology, and Cancer, Dr. Oh was inducted into the prestigious American Society for Clinical Investigation (ASCI) and has been repeatedly selected as a Top Doctor in New York Magazine, Castle Connolly, Best Doctors, and Super Doctors.
